Multivariate analysis to estimate the risk of TDF- over ABC-based antiretroviral therapy in the induction of more than 25% fall in eGFR according to baseline body weight.

TDF use was adjusted with the same variables indicated in Model 3, Table 3: age per 1 year, weight per 1 kg decrement, CD4 count per 1 /µl decrement, HIV viral load per log10/ml, serum creatinine per 1 mg/dl, concurrent use of nephrotoxic drugs, hepatitis B infection, and diabetes mellitus.